Genomic sequencing data guides treatment of metastatic triple-negative breast cancer patients
Unprecedented genomic sequencing of 14 metastatic TNBC patients yields potential drug targets
Unprecedented genomic sequencing of 14 metastatic TNBC patients yields potential drug targets
Researchers at Case Western Reserve University School of Medicine have identified a molecule linked to more aggressive forms of breast cancer – a discovery that could point the… read more.
There is no difference between proton radiotherapy (PRT) and intensity-modulated radiotherapy (IMRT) when comparing the toxicity among patients with prostate cancer at 12 months post-treatment according to a… read more.
Research presented at the American Society for Cell Biology (ASCB) annual meeting, 15-19 December 2012, San Francisco.
Laser-based measurements are proving to be a promising method for the assessment of osteoporosis. The team led by Professor Jussi Timonen has developed an ultrasound technique that… read more.
Ramon L. Rodriguez, M.D., Associate Professor, University of Florida Center for Movement Disorders & Neurorestoration.
Ramon L. Rodriguez, M.D., Associate Professor, University of Florida Center for Movement Disorders & Neurorestoration.
Dr Michael Okun, M.D., Professor, University of Florida Center for Movement Disorders & Neurorestoration.
Kelly D. Foote, M.D., Associate Professor, University of Florida Center for Movement Disorders & Neurorestoration. Dr. Foote was attending the Movement Disorder Society’s 16th International Congress of Parkinson’s… read more.
Erin M. Dunbar, M.D., Assistant Professor and Co-Director, Preston A. Wells, Jr. Center for Brain Tumor Therapy, Department of Neurosurgery, University of Florida.
by Marybeth Burke – Initial combination chemotherapy with bendamustine and rituximab more than doubled progression-free survival to nearly 6 years compared with standard R-CHOP therapy among patients with… read more.
by Marybeth Burke – Adding bevacizumab to chemotherapy halves the risk of the disease getting worse in platinum resistant patients with ovarian cancer,
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.